NCT07919236Recruiting
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin - the Association With Metabolic Control of Diabetes and Markers of Early Vascular Changes
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
The aim of the study is to assess the influence of continuous glucose monitoring (CGM) systems on metabolic control and quality of life in people with type 2 diabetes and overweight/obesity who are not treated with insulin. Additionally, the study aims to assess the association between metabolic control of diabetes and markers of early cardiovascular disease, taking into account the impact of CGM use.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 30 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Feb 2028
- Lead sponsor
- Medical University of Bialystok
- Diseases
- Type 2 diabetes
- NCT number
- NCT07919236
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Nov 2026 to the primary completion date, Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with insulin
- Acute infections, acute diabetes complications and/or unplanned hospitalisations in the previous month
- Use of steroids or immunosuppressive medications in the previous 3 months
- Chemotherapy, radiotherapy, immune therapy in the previous 3 months
Other illness
- Type 1 diabetes, gestational diabetes, other specific types of diabetes
- Skin lesions or dermatological conditions preventing proper sensor insertion
Lab values
- HbA1c \>10.0%
- Previous use of any continuous glucose monitoring system
- GFR \<30 ml/min
- Cognitive impairment and/or other conditions preventing proper use of continuous glucose monitoring system
- Lack of consent for the use of continuous glucose monitoring system
Other
- Pregnancy and/or breastfeeding
Who the study is looking for
- Age between 18 and 65 years (both inclusive)
- Type 2 diabetes diagnosed at least 6 months prior to entering the study
- Body mass index ≥25 kg/m2
- Diabetes treated with oral medications and/or GLP-1 receptor agonists and/or tirzepatide
- No modifications of diabetes treatment in the previous 3 months
- HbA1c between 7.5% and 10% (both inclusive)
- Oral and written informed consent for participation
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Bialystok, Department of Internal Medicine and Metabolic Diseases Coordinator of this site? Confirm its status | Bialystok | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.